Tag: Esprit BTK
CIRSE announces first patients enrolled in ORACLE and RESCUE studies of...
The Cardiovascular and Interventional Radiological Society of Europe (CIRSE) has announced the start of patient enrolment in ORACLE and RESCUE, two prospective observational studies...
Abbott secures CE mark for longer-length Esprit BTK system
Abbott has secured CE-mark approval for its new longer-length Esprit BTK system (76mm) for the treatment of chronic limb-threatening ischaemia (CLTI). The approval follows...
US FDA approves Abbott’s longer-length Esprit for severe PAD
The US Food and Drug Administration (FDA) has approved Abbott’s new longer-length Esprit BTK system for the treatment of chronic limb-threatening ischaemia (CLTI).
The longer-length...
Three-year data support drug-eluting resorbable scaffold as “durable, effective endovascular treatment...
Three-year data from the LIFE-BTK randomised controlled trial, presented today at the 2025 Vascular Interventional Advances (VIVA) conference (2–5 November, Las Vegas, USA), demonstrate the...
Two-year LIFE-BTK data show sustained benefits of drug-eluting resorbable scaffold for...
Presented today, late-breaking data from the second year of the LIFE-BTK clinical trial demonstrate the long-term effectiveness of the US Food and Drug Administration...
TCT 2024: Drug-eluting resorbable scaffold proves cost effective at one year...
A retrospective economic analysis of the LIFE-BTK trial has demonstrated the one-year cost-effectiveness of an everolimus-eluting resorbable scaffold over angioplasty for the treatment of...
